How to Treat Generalized Anxiety Disorder (GAD)
Start with either cognitive behavioral therapy (CBT) or an SSRI/SNRI as first-line treatment, with SSRIs (escitalopram, paroxetine, sertraline) and SNRIs (venlafaxine, duloxetine) being the preferred pharmacological options. 1, 2
First-Line Treatment Algorithm
Initial Treatment Choice
You have two equally effective first-line options 1, 2:
Pharmacotherapy:
- SSRIs: Escitalopram, paroxetine, or sertraline
- SNRIs: Venlafaxine or duloxetine
- These require 2-4 weeks before symptom relief begins 3
- Continue for 6-12 months after remission 2, 4
Psychotherapy:
- CBT has the highest level of evidence among psychotherapies 2, 5
- Can be delivered individually or in group format
- Particularly effective if patient prefers to avoid medications
Combined approach (CBT + medication) can be used from the start, especially in severe cases 6
Treatment Selection Factors
Choose pharmacotherapy when:
- Patient prefers medication
- Comorbid depression is present (antidepressants more effective than benzodiazepines) 7
- Rapid treatment initiation is needed
- Limited access to trained CBT therapists
Choose CBT when:
- Patient prefers non-pharmacological treatment 6
- Concerns about medication side effects or interactions
- No comorbid depression requiring medication
Treatment-Resistant GAD
If first-line treatment fails after adequate trial (8-12 weeks at therapeutic dose), consider these evidence-based options:
Augmentation Strategies (RCT Evidence)
The 2026 systematic review 1 identified these augmentation options for treatment-resistant GAD:
Antipsychotic augmentation:
- Risperidone (0.5-1.5 mg/day): Showed significant HAM-A score reduction vs placebo 1
- Quetiapine (25-150 mg/day): Mixed results - one small RCT positive 1, but larger RCTs negative 1
- Olanzapine: Mentioned as having RCT support 1
Other augmentation:
- Pregabalin (75-450 mg/day): RCT evidence but high dropout rates 1
- Consider as second-line option 6, 8
Alternative Strategies
If SSRI fails:
- Switch to different SSRI or SNRI 6
- Try pregabalin as monotherapy 6, 4
- Consider quetiapine monotherapy 6
If CBT fails:
- Add SSRI/SNRI pharmacotherapy 1
- Try Acceptance and Commitment Therapy (ACT) 1
- Try Mindfulness-Based Cognitive Therapy 1
Medications to Avoid or Use Cautiously
Benzodiazepines:
- NOT recommended for routine use due to addiction potential 2, 4
- Reserve only for short-term crisis situations
- High risk of dependence with chronic use
Buspirone:
Critical Treatment Considerations
Before declaring treatment failure:
- Verify adequate dose and duration (minimum 8-12 weeks) 6
- Assess medication adherence 6
- Re-evaluate diagnosis accuracy 6
- Identify comorbidities undermining response (depression, substance use, medical illness) 6
- Evaluate ongoing social stressors 6
Duration of treatment:
- Continue medications for 6-12 months after remission 2, 4
- Stopping earlier increases relapse risk within first year 7
- GAD is chronic and requires long-term management 7, 3
Treatment goals:
- Acute phase: Symptom improvement
- Long-term: Complete remission (resolution of symptoms AND functional impairment) 3
- Only 50-67% respond to first-line treatment, so be prepared to adjust 1
Common Pitfalls
- Starting benzodiazepines first: Creates dependence without addressing core pathology
- Stopping medications too early: High relapse rates if discontinued before 6 months
- Inadequate trial duration: Declaring failure before 8-12 weeks at therapeutic dose
- Ignoring comorbidities: Depression, substance use, and medical conditions significantly impact treatment response
- Not considering CBT: Equally effective as medication but often overlooked 2, 5